Compare Ascendis Pharma A/S (ASND) vs Church & Dwight Co., Inc. (CHD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Church & Dwight Co., Inc. — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Church & Dwight Co., Inc. trades at $97.48 (market cap $22.83B). The key difference: Church & Dwight Co., Inc. is the larger of the two by market cap, and Church & Dwight Co., Inc. pays a 1.28% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | CHD | |
|---|---|---|
Market Cap | $17.74B | $22.83B |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $105.26 |
52-Week Low | $163.32 | $81.60 |
Enterprise Value | $18.11B | $24.53B |
Dividend Yield | — | 1.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Church & Dwight (CHD) trades at $96.36, up 0.72% today, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 adjusted EPS of $0.95, exceeding expectations, driven by 5% organic sales growth. Recent acquisition of Miss Mouth's brand for $325 million aims to strengthen its fabric care portfolio. Cash flow trends show a net outflow in 2025, though operating cash flow remains robust at $1.22 billion.
Outlook remains positive with a consensus price target of $101.33, implying 5% upside, supported by strong analyst sentiment (53% buy ratings). Risks include margin pressure from inflation and competitive threats in consumer staples. The stock's valuation at 31.7x P/E requires sustained earnings growth to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Church & Dwight Co., Inc.
Church & Dwight is the leading producer of baking soda in the world. Beyond baking soda, the products in its portfolio have vast category reach, including laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its mix also includes Xtra, Trojan, OxiClean, First Response, Nair, L'il Critters/Vitafusion, Orajel, and WaterPik, which together with Arm & Hammer constitute more than 80% of its annual sales and profits. In early 2019, the firm announced the addition of Flawless, which manufactures electric shaving products for women. At the end of 2020, the firm acquired Zicam, a leading brand in the cough/cold-shortening category. Church & Dwight derives more than 80% of its sales from its home market in the U.S.
Read more on CHD →
